Baxter International (BAX) EBITDA (2009 - 2026)

Baxter International (BAX) has 18 years of EBITDA data on file, last reported at $66.0 million in Q1 2026.

• On a quarterly basis, EBITDA rose 13.79% year-over-year to $66.0 million in Q1 2026; TTM through Mar 2026 was $2.1 billion, a 31.32% decrease from a year earlier, with the FY2025 full-year figure at -$308.0 million, down 2300.0% from the prior year.
• EBITDA for Q1 2026 stood at $66.0 million, up from $58.0 million in the prior quarter.
• Over the last five years, EBITDA for BAX reached as high as $1.0 billion in Q3 2024 and fell as low as -$2.9 billion in Q3 2022.
• Historically, EBITDA has averaged $91.1 million across 5 years, with a median of $146.0 million in 2022.
• Across the five-year window, EBITDA tumbled 1456.52% in 2022 and soared 6164.71% in 2024, its largest moves.
• Year by year, EBITDA stood at -$312.0 million in 2022, then soared by 307.05% to $646.0 million in 2023, then surged by 48.45% to $959.0 million in 2024, then tumbled by 93.95% to $58.0 million in 2025, then increased by 13.79% to $66.0 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $66.0 million in Q1 2026, $58.0 million in Q1 2025, and $959.0 million in Q4 2024.